Skip to main content
. 2019 Sep 27;179(1):67–77. doi: 10.1007/s10549-019-05454-y

Fig. 3.

Fig. 3

The clinically relevant doses of SERDs exhibited similar efficacy when compared using an estrogen deprived model of aromatase inhibitor resistance. a Ovariectomized Nu:J mice bearing LTED (long-term estrogen deprived) xenograft tumors were randomized to treatment with vehicle (po qd), AZD9496 (10 mg/kg po qd), GDC0810 (25 mg/kg po qd), BZA (12.5 mg/kg po qd) or fulvestrant (25 mg/kg sc qw). Data presented indicate the average tumor volume for each group (mean ± SEM) at each time point. *As compared to the vehicle control, significant (p > 0.05) inhibition of tumor growth was observed for all treatments, while no significant differences were noted between treatments (2-way ANOVA analysis followed by Bonferroni multiple comparison test). b ER levels present in tumors harvested from mice included in a were analyzed by western blotting of tissue extracts. A significant (p < 0.05) decrease in ER levels was observed for all SERD treatments (1-way ANOVA analysis followed by Bonferroni multiple comparison test). Primary western blot images are included in Online Resource Fig. 3b. c Weights of uteri excised after euthanasia were recorded as a measure of uterine stimulation. *A significant (p < 0.05) increase in uterine weight was observed for all AZD9496 and GDC0810 (1-way ANOVA analysis followed by Bonferroni multiple comparison test)